213 related articles for article (PubMed ID: 37417300)
21. Patterns of recurrence in women with advanced and recurrent epithelial ovarian cancer treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.
Chambers LM; Yao M; Morton M; Gruner M; Chichura A; Horowitz M; Costales AB; Rose PG; Michener CM; Debernardo R
Gynecol Oncol; 2021 May; 161(2):389-395. PubMed ID: 33551202
[TBL] [Abstract][Full Text] [Related]
22. Cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy in patients with advanced ovarian cancer (OVHIPEC-1): final survival analysis of a randomised, controlled, phase 3 trial.
Aronson SL; Lopez-Yurda M; Koole SN; Schagen van Leeuwen JH; Schreuder HWR; Hermans RHM; de Hingh IHJT; van Gent MDJM; Arts HJG; van Ham MAPC; van Dam PA; Vuylsteke P; Aalbers AGJ; Verwaal VJ; Van de Vijver KK; Aaronson NK; Sonke GS; van Driel WJ
Lancet Oncol; 2023 Oct; 24(10):1109-1118. PubMed ID: 37708912
[TBL] [Abstract][Full Text] [Related]
23. HIPEC after neoadjuvant chemotherapy is associated with acceptable toxicity and favorable quality of life in newly diagnosed advanced ovarian cancer patients.
Menzies AV; Usher EC; Hsu FC; Levine EA; Lentz SS; Kelly MG
Gynecol Oncol; 2022 Nov; 167(2):234-238. PubMed ID: 36085091
[TBL] [Abstract][Full Text] [Related]
24. Assessing feasibility and perioperative outcomes with minimally invasive surgery compared with laparotomy for interval debulking surgery with hyperthermic intraperitoneal chemotherapy for advanced epithelial ovarian cancer.
Morton M; Chambers LM; Costales AB; Chichura A; Gruner M; Horowitz MP; Rose PG; Yao M; Debernardo R; Michener C
Gynecol Oncol; 2021 Jan; 160(1):45-50. PubMed ID: 33067001
[TBL] [Abstract][Full Text] [Related]
25. Hyperthermic Intraperitoneal Chemotherapy in Ovarian Cancer.
van Driel WJ; Koole SN; Sikorska K; Schagen van Leeuwen JH; Schreuder HWR; Hermans RHM; de Hingh IHJT; van der Velden J; Arts HJ; Massuger LFAG; Aalbers AGJ; Verwaal VJ; Kieffer JM; Van de Vijver KK; van Tinteren H; Aaronson NK; Sonke GS
N Engl J Med; 2018 Jan; 378(3):230-240. PubMed ID: 29342393
[TBL] [Abstract][Full Text] [Related]
26. A novel treatment protocol with 6 cycles of neoadjuvant chemotherapy followed by cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) in stage III primary ovarian cancer.
Marrelli D; Petrioli R; Cassetti D; D'Ignazio A; Marsili S; Mazzei MA; Lazzi S; Roviello F
Surg Oncol; 2021 Jun; 37():101523. PubMed ID: 33545658
[TBL] [Abstract][Full Text] [Related]
27. Outcomes for Elderly Ovarian Cancer Patients Treated with Cytoreductive Surgery Plus Hyperthermic Intraperitoneal Chemotherapy (CRS/HIPEC).
Zambrano-Vera K; Sardi A; Lopez-Ramirez F; Sittig M; Munoz-Zuluaga C; Nieroda C; Gushchin V; Diaz-Montes T
Ann Surg Oncol; 2021 Aug; 28(8):4655-4666. PubMed ID: 33393042
[TBL] [Abstract][Full Text] [Related]
28. Combined Interval Cytoreductive Surgery and Carboplatin-Based Hyperthermic Intraperitoneal Chemotherapy in Advanced Primary High-Grade Serous Ovarian Cancer.
Brault C; Brind'Amour A; de Guerke L; Auclair MH; Sideris L; Dubé P; Soucisse M; Tremblay JF; Bernard L; Piedimonte S; Fortin S
Curr Oncol; 2023 Dec; 30(12):10272-10282. PubMed ID: 38132382
[TBL] [Abstract][Full Text] [Related]
29. Pattern of recurrence after interval cytoreductive surgery and HIPEC following neoadjuvant chemotherapy in primary advanced stage IIIC/IVA epithelial ovarian cancer.
Sinukumar S; Damodaran D; Ray M; Mehta S; Paul L; Bhatt A
Eur J Surg Oncol; 2021 Jun; 47(6):1427-1433. PubMed ID: 33509612
[TBL] [Abstract][Full Text] [Related]
30. Critical Analysis of Stage IV Epithelial Ovarian Cancer Patients after Treatment with Neoadjuvant Chemotherapy followed by Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (CRS/HIPEC).
Munoz-Zuluaga CA; Sardi A; Sittig M; Gushchin V; King MC; Nieroda C; Lopez-Ramirez F; Diaz-Montes TP
Int J Surg Oncol; 2020; 2020():1467403. PubMed ID: 33381312
[TBL] [Abstract][Full Text] [Related]
31. Prolonged hyperthermic intraperitoneal chemotherapy duration with 90 minutes cisplatin might increase overall survival in gastric cancer patients with peritoneal metastases.
Steinhoff H; Acs M; Blaj S; Dank M; Herold M; Herold Z; Herzberg J; Sanchez-Velazquez P; Strate T; Szasz AM; Piso P
World J Gastroenterol; 2023 May; 29(18):2850-2863. PubMed ID: 37274066
[TBL] [Abstract][Full Text] [Related]
32. Developing a hyperthermic intraperitoneal chemotherapy (HIPEC) gynecologic oncology program: a Canadian experience.
Neveu J; Tremblay E; Mercier F; Garneau S; Cormier B
Int J Gynecol Cancer; 2023 Dec; 33(12):1957-1965. PubMed ID: 38011988
[TBL] [Abstract][Full Text] [Related]
33. Quality of life outcomes from the randomized trial of hyperthermic intraperitoneal chemotherapy following cytoreductive surgery for primary ovarian cancer (KOV-HIPEC-01).
Kim JH; Lee DE; Lee Y; Ha HI; Chang YJ; Chang SJ; Park SY; Lim MC
J Gynecol Oncol; 2022 Jul; 33(4):e54. PubMed ID: 35712968
[TBL] [Abstract][Full Text] [Related]
34. A phase 2 trial of short-course Hyperthermic IntraPeritoneal Chemotherapy (HIPEC) at interval cytoreductive surgery (iCRS) for advanced ovarian cancer.
Batista TP; Carneiro VCG; Tancredi R; Badiglian Filho L; Rangel RLC; Lopes A; Sarmento BJQ; Leão CS
Rev Col Bras Cir; 2022; 49():e20223135. PubMed ID: 35239855
[TBL] [Abstract][Full Text] [Related]
35. Outcomes after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal dissemination from ovarian carcinosarcoma.
Lopez-Ramirez F; Sardi A; Studeman K; King MC; Falla-Zuniga LF; Nikiforchin A; Baron E; Nieroda C; Gushchin V; Diaz-Montes T
Eur J Surg Oncol; 2023 Aug; 49(8):1495-1503. PubMed ID: 37068984
[TBL] [Abstract][Full Text] [Related]
36. Utility of hyperthermic intraperitoneal chemotherapy in cases of incomplete cytoreductive surgery.
Mangieri CW; Moaven O; Valenzuela CD; Erali RA; Votanopoulos KI; Shen P; Levine EA
J Surg Oncol; 2022 Mar; 125(4):703-711. PubMed ID: 34841542
[TBL] [Abstract][Full Text] [Related]
37. Treatment of peritoneal carcinomatosis from ovarian cancer by surgical cytoreduction and hyperthermic intraperitoneal chemotherapy (HIPEC).
Robella M; Vaira M; Marsanic P; Mellano A; Borsano A; Cinquegrana A; Sottile A; De Simone M
Minerva Chir; 2014 Feb; 69(1):27-35. PubMed ID: 24675244
[TBL] [Abstract][Full Text] [Related]
38. Hyperthermic Intraperitoneal Chemotherapy in Ovarian Cancer.
Gelissen JH; Adjei NN; McNamara B; Mutlu L; Harold JA; Clark M; Altwerger G; Dottino PR; Huang GS; Santin AD; Azodi M; Ratner E; Schwartz PE; Andikyan V
Ann Surg Oncol; 2023 Sep; 30(9):5597-5609. PubMed ID: 37358686
[TBL] [Abstract][Full Text] [Related]
39. Predictors of progression in high-grade appendiceal or colorectal peritoneal carcinomatosis after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.
Baumgartner JM; Tobin L; Heavey SF; Kelly KJ; Roeland EJ; Lowy AM
Ann Surg Oncol; 2015 May; 22(5):1716-21. PubMed ID: 25145504
[TBL] [Abstract][Full Text] [Related]
40. Hyperthermic intraoperative intraperitoneal chemotherapy (HIPEC) with primary or secondary cytoreductive surgery in the treatment of advanced epithelial ovarian cancer.
Manzanedo I; Pereira F; Pérez-Viejo E; Serrano Á; Hernández-García M; Martínez-Torres B; Rihuete-Caro C; Calzas J; Cueto M
Minerva Ginecol; 2017 Apr; 69(2):119-127. PubMed ID: 27415829
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
